Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

AROA BIOSURGERY LIMITED Share Issue/Capital Change 2021

Dec 6, 2021

64426_rns_2021-12-06_f020a674-2b73-44b9-ae45-5b941eeefc80.pdf

Share Issue/Capital Change

Open in viewer

Opens in your device viewer

ASX ANNOUNCEMENT/MEDIA RELEASE 7 December 2021

==> picture [113 x 51] intentionally omitted <==

SECTIO N 70 8A NOTICE

This notice is given by Aroa Biosurgery Limited ( Company ) under Section 708A(5)(e) of the Corporations Act 2001 (Cth) (Corporations Act).

The Company hereby confirms that:

  • (a) On 7 December 2021 it has issued 433,317 fully paid ordinary shares as the result of the cashless (net settled) exercise of 472,500 unlisted options held by employees in the Company.

  • (b) the shares referred to in paragraph (a) above were issued without disclosure to investors under Part 6D.2 of the Corporations Act;

  • (c) the Company is providing this notice under paragraph 5(e) of Section 708A of the Corporations Act;

  • (d) as at the date of this notice the Company, as a disclosing entity under the Corporations Act, has complied with:

  • (i) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and

  • (ii) Section 674 of the Corporations Act as it applies to the Company; and

  • (e) as at the date of this announcement, there is no excluded information of the type referred to in Sections 708A(7) and 708A(8) of the Corporations Act.

An Appendix 2A document relating to the issue of shares will follow shortly.

< ENDS >

Authorised on behalf of the Aroa Biosurgery Board of Directors by Brian Ward, CEO.

About AROA™

Aroa Biosurgery is a soft-tissue regeneration company committed to ‘unlocking regenerative healing for everybody’. We develop, manufacture, sell and distribute medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Our products are developed from a proprietary AROA ECM™ technology platform, a novel extracellular matrix biomaterial derived from ovine (sheep) forestomach. AROA’s products have been used in more than four and a half million procedures to date, with distribution into our key market of the United States via our direct sales force and our partner TELA Bio. Founded in 2008, AROA is headquartered in Auckland, New Zealand and is listed on the Australian Securities Exchange (ASX:ARX). www.aroabio.com/

Contacts

Investor Simon Hinsley Investor Relations [email protected] + 61 401 809 653

==> picture [273 x 34] intentionally omitted <==

AROA BIOSURGERY LIMITED ARBN 638 867 473 NZCN 1980577 64 Richard Pearse Drive, Auckland 2022, New Zealand AROABIO.COM

ASX ANNOUNCEMENT/MEDIA RELEASE 7 December 2021

==> picture [113 x 51] intentionally omitted <==

Media Australia New Zealand Matthew Wright Piet De Jong [email protected] [email protected] +61 451 896 420 +64 21 812 766

==> picture [273 x 34] intentionally omitted <==

AROA BIOSURGERY LIMITED ARBN 638 867 473 NZCN 1980577 64 Richard Pearse Drive, Auckland 2022, New Zealand AROABIO.COM